TheraGenetics Announces Acquisition by Avacta Group plc

CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--TheraGenetics Limited, a personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of central nervous system (CNS) disorders, announced today that the Company has been acquired by publicly traded Avacta Group PLC. UK-based Avacta seeks to develop innovative detection and analysis technology aimed primarily at the pharmaceutical and healthcare markets. TheraGenetics is focused on developing pharmacogenetic diagnostic tests for schizophrenia, depression, bipolar disorder, Alzheimer’s disease and ADHD (attention deficit hyperactivity disorder). The acquisition brings together two highly complementary UK-based companies focused on developing diagnostics at the molecular level for the treatment of critical diseases where there remains significant unmet medical need.